Browse the corpus

Abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), is used to manage and treat osteoporosis. Osteoporosis is characterized by reduced bone mineral density due to changes in bone microstructure, resulting in an elevated risk of fractures. The US Food and Drug Administration (FDA) has approved abaloparatide use in postmenopausal women at high risk of fracture due to osteoporosis. In addition, abaloparatide is frequently prescribed for individuals who exhibit intolerance to or have not responded to conventional osteoporosis treatments. In a double-blind, controlled, randomized phase II clinical trial, the safety and efficacy of abaloparatide demonstrated superiority in enhancing overall bone mineral density compared to teriparatide and placebo within these treatment groups. As osteoporosis primarily affects postmenopausal women, it is crucial to provide clinicians with essential knowledge about abaloparatide, which is vital to ensure optimal patient care and prevent disease progression. This activity reviews the indications, mechanism of action, administration, pharmacokinetics, and associated warnings related to abaloparatide. By enhancing the expertise of healthcare professionals with evidence-based strategies, this activity seeks to empower clinicians to incorporate abaloparatide into clinical practice seamlessly. This contribution aims to improve patient outcomes in the management of osteoporosis. Objectives: Identify appropriate candidates for abaloparatide therapy, considering postmenopausal women at high risk of fractures and those intolerant or unresponsive to traditional osteoporosis treatments. Implement proper administration techniques, emphasizing subcutaneous injection and supplementing with calcium and vitamin D if dietary intake is inadequate. Select appropriate dosages and durations of abaloparatide based on individual patient characteristics and response to treatment. Collaborate with interprofessional healthcare teams, fostering a holistic approach to osteoporosis management, and seek specialist input when necessary. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Symptoms of abaloparatide toxicity include headache, nausea, asthenia, and vertigo. Management of Overdose No specific antidote for abaloparatide toxicity currently exists. If an overdose is suspected, abaloparatide should be discontinued by closely monitoring calcium and phosphorus levels. Supportive measures should be implemented.

Osteoporosis is a chronic disease that decreases BMD and increases the risk of fractures. Managing osteoporosis requires an empathetic interdisciplinary team of rheumatologists, endocrinologists, orthopedic surgeons, nutritionists, nurses, nuclear medicine technicians, and physical therapists to diagnose, treat, and rehabilitate patients. Abaloparatide is a human PTHrP analog that is FDA-approved in postmenopausal women with osteoporosis at a high fracture risk to reduce vertebral and nonvertebral fractures. Patients should be educated on postmenopausal osteoporosis, self-treatment with abaloparatide, and possible adverse effects. In addition, dietician intervention is beneficial in ensuring the patient's adequate calcium and vitamin D intake. Individuals who experience fractures or bone breakage should be treated by orthopedic surgeons and physical therapists for rehabilitation, leading to improved quality of life. Rheumatologists and endocrinologists should maintain follow-ups to monitor calcium and phosphorus levels and assess for hypercalcemia or other adverse effects. Abaloparatide is associated with an increased risk of osteosarcoma. Thus, individuals taking abaloparatide may require a nuclear medicine technician to monitor them for the development of malignancies or possible metastasis. The interprofessional team should be continuously updated on the patient's status and osteoporosis management guidelines. Abaloparatide treatment is self-administered in an environment where the patient can sit or stand if orthostatic hypotension occurs. Patients without adequate calcium or vitamin D should be advised to take supplements. Abaloparatide use is indicated in postmenopausal women and not in females of reproductive potential. The effects of abaloparatide on pregnancy, breastfeeding mothers, breastfed infants, milk production, and the pediatric population are unknown. Abaloparatide is not recommended in pediatric patients with open epiphyses or genetic predispositions to bone malignancies.[31] Patient education, improved clinician-patient communication, and ease of medication administration all play a significant role in successful treatment initiation, management, and improvement of patient outcomes. An interprofessional team approach and open communication between clinicians optimize the treatment response to abaloparatide.